{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,23]],"date-time":"2026-09-23T20:48:03Z","timestamp":1790196483920,"version":"4.1.0"},"reference-count":95,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,4,26]],"date-time":"2026-04-26T00:00:00Z","timestamp":1777161600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2026,6,15]],"date-time":"2026-06-15T00:00:00Z","timestamp":1781481600000},"content-version":"vor","delay-in-days":50,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Breast Cancer Res"],"DOI":"10.1186\/s13058-026-02285-w","type":"journal-article","created":{"date-parts":[[2026,4,26]],"date-time":"2026-04-26T08:04:44Z","timestamp":1777190684000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Tumor-infiltrating lymphocytes in triple-negative breast cancer: molecular mechanisms, spatial regulation, and therapeutic implications"],"prefix":"10.1186","volume":"28","author":[{"given":"Yuefeng","family":"Li","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhian","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jiangfeng","family":"Dai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,4,26]]},"reference":[{"issue":"1","key":"2285_CR1","first-page":"12","volume":"74","author":"RL Siegel","year":"2024","unstructured":"Siegel RL, Giaquinto AN, Jemal A. Cancer statistics, 2024. CA Cancer J Clin. 2024;74(1):12\u201349.","journal-title":"CA Cancer J Clin"},{"issue":"6","key":"2285_CR2","first-page":"477","volume":"74","author":"AN Giaquinto","year":"2024","unstructured":"Giaquinto AN, Sung H, Newman LA, Freedman RA, Smith RA, Star J, et al. Breast cancer statistics 2024. CA Cancer J Clin. 2024;74(6):477\u201395.","journal-title":"CA Cancer J Clin"},{"issue":"1","key":"2285_CR3","doi-asserted-by":"publisher","first-page":"41","DOI":"10.1097\/PPO.0000000000000498","volume":"27","author":"A Marra","year":"2021","unstructured":"Marra A, Curigliano G. Adjuvant and Neoadjuvant Treatment of Triple-Negative Breast Cancer With Chemotherapy. Cancer J. 2021;27(1):41\u20139.","journal-title":"Cancer J"},{"key":"2285_CR4","doi-asserted-by":"crossref","unstructured":"Bergin ART, Loi S: Triple-negative breast cancer: recent treatment advances. F1000Res 2019;8","DOI":"10.12688\/f1000research.18888.1"},{"issue":"6","key":"2285_CR5","doi-asserted-by":"publisher","first-page":"567","DOI":"10.1080\/13543784.2022.2049232","volume":"31","author":"E Agostinetto","year":"2022","unstructured":"Agostinetto E, Losurdo A, Nader-Marta G, Santoro A, Punie K, Barroso R, et al. Progress and pitfalls in the use of immunotherapy for patients with triple negative breast cancer. Expert Opin Investig Drugs. 2022;31(6):567\u201391.","journal-title":"Expert Opin Investig Drugs"},{"issue":"2","key":"2285_CR6","doi-asserted-by":"publisher","first-page":"227","DOI":"10.1001\/jamaoncol.2023.5033","volume":"10","author":"P Sharma","year":"2024","unstructured":"Sharma P, Stecklein SR, Yoder R, Staley JM, Schwensen K, O\u2019Dea A, et al. Clinical and biomarker findings of neoadjuvant pembrolizumab and carboplatin plus docetaxel in triple-negative breast cancer: NeoPACT phase 2 clinical trial. JAMA Oncol. 2024;10(2):227\u201335.","journal-title":"JAMA Oncol"},{"issue":"4","key":"2285_CR7","doi-asserted-by":"publisher","first-page":"1318","DOI":"10.1016\/j.gendis.2022.07.024","volume":"10","author":"S Kumar","year":"2023","unstructured":"Kumar S, Chatterjee M, Ghosh P, Ganguly KK, Basu M, Ghosh MK. Targeting PD-1\/PD-L1 in cancer immunotherapy: An effective strategy for treatment of triple-negative breast cancer (TNBC) patients. Genes Dis. 2023;10(4):1318\u201350.","journal-title":"Genes Dis"},{"issue":"1","key":"2285_CR8","doi-asserted-by":"publisher","first-page":"108","DOI":"10.1186\/s12943-024-02023-w","volume":"23","author":"X Lin","year":"2024","unstructured":"Lin X, Kang K, Chen P, Zeng Z, Li G, Xiong W, et al. Regulatory mechanisms of PD-1\/PD-L1 in cancers. Mol Cancer. 2024;23(1):108.","journal-title":"Mol Cancer"},{"issue":"13","key":"2285_CR9","doi-asserted-by":"publisher","first-page":"10684","DOI":"10.3390\/ijms241310684","volume":"24","author":"S Wang","year":"2023","unstructured":"Wang S, Khan FI. Investigation of molecular interactions mechanism of pembrolizumab and PD-1. Int J Mol Sci. 2023;24(13):10684.","journal-title":"Int J Mol Sci"},{"issue":"10265","key":"2285_CR10","doi-asserted-by":"publisher","first-page":"1817","DOI":"10.1016\/S0140-6736(20)32531-9","volume":"396","author":"J Cortes","year":"2020","unstructured":"Cortes J, Cescon DW, Rugo HS, Nowecki Z, Im SA, Yusof MM, et al. Pembrolizumab plus chemotherapy versus placebo plus chemotherapy for previously untreated locally recurrent inoperable or metastatic triple-negative breast cancer (KEYNOTE-355): a randomised, placebo-controlled, double-blind, phase 3 clinical trial. Lancet. 2020;396(10265):1817\u201328.","journal-title":"Lancet"},{"issue":"3","key":"2285_CR11","doi-asserted-by":"publisher","first-page":"217","DOI":"10.1056\/NEJMoa2202809","volume":"387","author":"J Cortes","year":"2022","unstructured":"Cortes J, Rugo HS, Cescon DW, Im SA, Yusof MM, Gallardo C, et al. Pembrolizumab plus chemotherapy in advanced triple-negative breast cancer. N Engl J Med. 2022;387(3):217\u201326.","journal-title":"N Engl J Med"},{"issue":"9","key":"2285_CR12","doi-asserted-by":"publisher","first-page":"810","DOI":"10.1056\/NEJMoa1910549","volume":"382","author":"P Schmid","year":"2020","unstructured":"Schmid P, Cortes J, Pusztai L, McArthur H, K\u00fcmmel S, Bergh J, et al. Pembrolizumab for early triple-negative breast cancer. N Engl J Med. 2020;382(9):810\u201321.","journal-title":"N Engl J Med"},{"issue":"7","key":"2285_CR13","first-page":"2885","volume":"25","author":"Y Zhou","year":"2021","unstructured":"Zhou Y, Tian Q, Wang BY, Yang J, Zhao SD, Yang J. The prognostic significance of TILs as a biomarker in triple-negative breast cancer: what is the role of TILs in TME of TNBC? Eur Rev Med Pharmacol Sci. 2021;25(7):2885\u201397.","journal-title":"Eur Rev Med Pharmacol Sci"},{"key":"2285_CR14","doi-asserted-by":"publisher","first-page":"59","DOI":"10.1186\/s40425-016-0165-6","volume":"4","author":"SE Stanton","year":"2016","unstructured":"Stanton SE, Disis ML. Clinical significance of tumor-infiltrating lymphocytes in breast cancer. J Immunother Cancer. 2016;4:59.","journal-title":"J Immunother Cancer"},{"issue":"3","key":"2285_CR15","doi-asserted-by":"publisher","first-page":"463","DOI":"10.1016\/j.ccell.2018.01.011","volume":"33","author":"A Costa","year":"2018","unstructured":"Costa A, Kieffer Y, Scholer-Dahirel A, Pelon F, Bourachot B, Cardon M, et al. Fibroblast Heterogeneity and Immunosuppressive Environment in Human Breast Cancer. Cancer Cell. 2018;33(3):463-479.e410.","journal-title":"Cancer Cell"},{"issue":"8","key":"2285_CR16","doi-asserted-by":"publisher","first-page":"e1346","DOI":"10.1002\/ctm2.1346","volume":"13","author":"Q Wang","year":"2023","unstructured":"Wang Q, Sun K, Liu R, Song Y, Lv Y, Bi P, et al. Single-cell transcriptome sequencing of B-cell heterogeneity and tertiary lymphoid structure predicts breast cancer prognosis and neoadjuvant therapy efficacy. Clin Transl Med. 2023;13(8):e1346.","journal-title":"Clin Transl Med"},{"issue":"2","key":"2285_CR17","doi-asserted-by":"publisher","first-page":"223","DOI":"10.3390\/cells10020223","volume":"10","author":"MV Dieci","year":"2021","unstructured":"Dieci MV, Miglietta F, Guarneri V. Immune infiltrates in breast cancer: recent updates and clinical implications. Cells. 2021;10(2):223.","journal-title":"Cells"},{"issue":"1","key":"2285_CR18","doi-asserted-by":"publisher","first-page":"92","DOI":"10.1186\/s12943-024-01990-4","volume":"23","author":"M Kundu","year":"2024","unstructured":"Kundu M, Butti R, Panda VK, Malhotra D, Das S, Mitra T, et al. Modulation of the tumor microenvironment and mechanism of immunotherapy-based drug resistance in breast cancer. Mol Cancer. 2024;23(1):92.","journal-title":"Mol Cancer"},{"issue":"1","key":"2285_CR19","doi-asserted-by":"publisher","first-page":"141","DOI":"10.1007\/s00404-013-2922-9","volume":"289","author":"JB Engel","year":"2014","unstructured":"Engel JB, Honig A, Kapp M, Hahne JC, Meyer SR, Dietl J, et al. Mechanisms of tumor immune escape in triple-negative breast cancers (TNBC) with and without mutated BRCA 1. Arch Gynecol Obstet. 2014;289(1):141\u20137.","journal-title":"Arch Gynecol Obstet"},{"issue":"1","key":"2285_CR20","doi-asserted-by":"publisher","first-page":"133","DOI":"10.1186\/s12943-020-01250-1","volume":"19","author":"J Zheng","year":"2020","unstructured":"Zheng J, Mo J, Zhu T, Zhuo W, Yi Y, Hu S, et al. Comprehensive elaboration of the cGAS-STING signaling axis in cancer development and immunotherapy. Mol Cancer. 2020;19(1):133.","journal-title":"Mol Cancer"},{"issue":"2","key":"2285_CR21","doi-asserted-by":"publisher","first-page":"75","DOI":"10.1038\/s41577-022-00751-y","volume":"23","author":"Y Zhao","year":"2023","unstructured":"Zhao Y, Simon M, Seluanov A, Gorbunova V. DNA damage and repair in age-related inflammation. Nat Rev Immunol. 2023;23(2):75\u201389.","journal-title":"Nat Rev Immunol"},{"key":"2285_CR22","doi-asserted-by":"publisher","first-page":"1150705","DOI":"10.3389\/fimmu.2023.1150705","volume":"14","author":"HTW Blest","year":"2023","unstructured":"Blest HTW, Chauveau L. cGAMP the travelling messenger. Front Immunol. 2023;14:1150705.","journal-title":"Front Immunol"},{"issue":"1","key":"2285_CR23","doi-asserted-by":"publisher","first-page":"81","DOI":"10.1186\/s13045-020-00916-z","volume":"13","author":"M Jiang","year":"2020","unstructured":"Jiang M, Chen P, Wang L, Li W, Chen B, Liu Y, et al. cGAS-STING, an important pathway in cancer immunotherapy. J Hematol Oncol. 2020;13(1):81.","journal-title":"J Hematol Oncol"},{"issue":"1","key":"2285_CR24","doi-asserted-by":"publisher","first-page":"136","DOI":"10.1186\/s12943-020-01247-w","volume":"19","author":"Y Wang","year":"2020","unstructured":"Wang Y, Luo J, Alu A, Han X, Wei Y, Wei X. cGAS-STING pathway in cancer biotherapy. Mol Cancer. 2020;19(1):136.","journal-title":"Mol Cancer"},{"key":"2285_CR25","doi-asserted-by":"publisher","first-page":"795401","DOI":"10.3389\/fimmu.2021.795401","volume":"12","author":"Y Gan","year":"2021","unstructured":"Gan Y, Li X, Han S, Liang Q, Ma X, Rong P, et al. The cGAS\/STING pathway: a novel target for cancer therapy. Front Immunol. 2021;12:795401.","journal-title":"Front Immunol"},{"issue":"35","key":"2285_CR26","doi-asserted-by":"publisher","first-page":"e2308890","DOI":"10.1002\/advs.202308890","volume":"11","author":"Z Tong","year":"2024","unstructured":"Tong Z, Zou JP, Wang SY, Luo WW, Wang YY. Activation of the cGAS-STING-IRF3 Axis by Type I and II interferons contributes to host defense. Adv Sci (Weinh). 2024;11(35):e2308890.","journal-title":"Adv Sci (Weinh)"},{"issue":"1","key":"2285_CR27","doi-asserted-by":"publisher","first-page":"2921","DOI":"10.1038\/s41467-019-10970-y","volume":"10","author":"E Platanitis","year":"2019","unstructured":"Platanitis E, Demiroz D, Schneller A, Fischer K, Capelle C, Hartl M, et al. A molecular switch from STAT2-IRF9 to ISGF3 underlies interferon-induced gene transcription. Nat Commun. 2019;10(1):2921.","journal-title":"Nat Commun"},{"issue":"12","key":"2285_CR28","doi-asserted-by":"publisher","first-page":"1452","DOI":"10.1038\/s43018-022-00468-w","volume":"3","author":"N Samson","year":"2022","unstructured":"Samson N, Ablasser A. The cGAS-STING pathway and cancer. Nat Cancer. 2022;3(12):1452\u201363.","journal-title":"Nat Cancer"},{"issue":"5","key":"2285_CR29","doi-asserted-by":"publisher","first-page":"859","DOI":"10.1016\/j.immuni.2021.01.012","volume":"54","author":"AJ Ozga","year":"2021","unstructured":"Ozga AJ, Chow MT, Luster AD. Chemokines and the immune response to cancer. Immunity. 2021;54(5):859\u201374.","journal-title":"Immunity"},{"issue":"1","key":"2285_CR30","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1038\/s41523-023-00609-z","volume":"10","author":"M Chen","year":"2024","unstructured":"Chen M, Yu S, van der Sluis T, Zwager MC, Schroder CP, van der Vegt B, et al. cGAS-STING pathway expression correlates with genomic instability and immune cell infiltration in breast cancer. NPJ Breast Cancer. 2024;10(1):1.","journal-title":"NPJ Breast Cancer"},{"issue":"4","key":"2285_CR31","doi-asserted-by":"publisher","first-page":"366","DOI":"10.1158\/2159-8290.CD-11-0206","volume":"2","author":"NJ Birkbak","year":"2012","unstructured":"Birkbak NJ, Wang ZC, Kim JY, Eklund AC, Li Q, Tian R, et al. Telomeric allelic imbalance indicates defective DNA repair and sensitivity to DNA-damaging agents. Cancer Discov. 2012;2(4):366\u201375.","journal-title":"Cancer Discov"},{"issue":"9","key":"2285_CR32","doi-asserted-by":"publisher","first-page":"1699","DOI":"10.1158\/2159-8290.CD-22-0649","volume":"14","author":"JK Meena","year":"2024","unstructured":"Meena JK, Wang JH, Neill NJ, Keough D, Putluri N, Katsonis P, et al. MYC Induces Oncogenic Stress through RNA Decay and Ribonucleotide Catabolism in Breast Cancer. Cancer Discov. 2024;14(9):1699\u2013716.","journal-title":"Cancer Discov"},{"issue":"22","key":"2285_CR33","doi-asserted-by":"publisher","first-page":"12031","DOI":"10.3390\/ijms252212031","volume":"25","author":"AN Guerrieri","year":"2024","unstructured":"Guerrieri AN, Hattinger CM, Marchesini F, Melloni M, Serra M, Ibrahim T, et al. The Interplay between the MYC oncogene and ribosomal proteins in osteosarcoma onset and progression: potential mechanisms and indication of candidate therapeutic targets. Int J Mol Sci. 2024;25(22):12031.","journal-title":"Int J Mol Sci"},{"issue":"1","key":"2285_CR34","doi-asserted-by":"publisher","first-page":"6579","DOI":"10.1038\/s41467-022-34000-6","volume":"13","author":"D Zimmerli","year":"2022","unstructured":"Zimmerli D, Brambillasca CS, Talens F, Bhin J, Linstra R, Romanens L, et al. MYC promotes immune-suppression in triple-negative breast cancer via inhibition of interferon signaling. Nat Commun. 2022;13(1):6579.","journal-title":"Nat Commun"},{"issue":"1","key":"2285_CR35","doi-asserted-by":"publisher","first-page":"5154","DOI":"10.1038\/s41467-025-60293-4","volume":"16","author":"WC Liu","year":"2025","unstructured":"Liu WC, Wei YH, Chen JF, Xing XL, Jia HX, Yang XY, et al. Inhibition of tumor-intrinsic NAT10 enhances antitumor immunity by triggering type I interferon response via MYC\/CDK2\/DNMT1 pathway. Nat Commun. 2025;16(1):5154.","journal-title":"Nat Commun"},{"key":"2285_CR36","doi-asserted-by":"publisher","first-page":"198","DOI":"10.1016\/j.semcancer.2020.05.010","volume":"72","author":"KK Wong","year":"2021","unstructured":"Wong KK. DNMT1: A key drug target in triple-negative breast cancer. Semin Cancer Biol. 2021;72:198\u2013213.","journal-title":"Semin Cancer Biol"},{"issue":"7","key":"2285_CR37","doi-asserted-by":"publisher","first-page":"e002528","DOI":"10.1136\/jitc-2021-002528","volume":"9","author":"SY Wu","year":"2021","unstructured":"Wu SY, Xiao Y, Wei JL, Xu XE, Jin X, Hu X, et al. MYC suppresses STING-dependent innate immunity by transcriptionally upregulating DNMT1 in triple-negative breast cancer. J Immunotherapy Cancer. 2021;9(7):e002528.","journal-title":"J Immunotherapy Cancer"},{"issue":"1","key":"2285_CR38","doi-asserted-by":"publisher","first-page":"5665","DOI":"10.1038\/s41467-023-40841-6","volume":"14","author":"ZO Doha","year":"2023","unstructured":"Doha ZO, Wang X, Calistri NL, Eng J, Daniel CJ, Ternes L, et al. MYC deregulation and PTEN loss model tumor and stromal heterogeneity of aggressive triple-negative breast cancer. Nat Commun. 2023;14(1):5665.","journal-title":"Nat Commun"},{"key":"2285_CR39","doi-asserted-by":"publisher","first-page":"41","DOI":"10.1016\/j.canlet.2021.12.003","volume":"527","author":"C Chai","year":"2022","unstructured":"Chai C, Wu HH, Abuetabh Y, Sergi C, Leng R. Regulation of the tumor suppressor PTEN in triple-negative breast cancer. Cancer Lett. 2022;527:41\u20138.","journal-title":"Cancer Lett"},{"key":"2285_CR40","doi-asserted-by":"publisher","first-page":"10689","DOI":"10.1038\/ncomms10689","volume":"7","author":"SR Shinde","year":"2016","unstructured":"Shinde SR, Maddika S. PTEN modulates EGFR late endocytic trafficking and degradation by dephosphorylating Rab7. Nat Commun. 2016;7:10689.","journal-title":"Nat Commun"},{"issue":"1","key":"2285_CR41","doi-asserted-by":"publisher","first-page":"44","DOI":"10.1158\/0008-5472.CAN-19-1310","volume":"80","author":"JL Ritter","year":"2020","unstructured":"Ritter JL, Zhu Z, Thai TC, Mahadevan NR, Mertins P, Knelson EH, et al. Phosphorylation of RAB7 by TBK1\/IKKepsilon regulates innate immune signaling in triple-negative breast cancer. Cancer Res. 2020;80(1):44\u201356.","journal-title":"Cancer Res"},{"key":"2285_CR42","doi-asserted-by":"publisher","first-page":"962389","DOI":"10.3389\/fcell.2022.962389","volume":"10","author":"X Cao","year":"2022","unstructured":"Cao X, Zhou X, Chen C, Wang Z, Sun Q. Identification of tumor antigens and immunogenic cell death-related subtypes for the improvement of immunotherapy of breast cancer. Front Cell Dev Biol. 2022;10:962389.","journal-title":"Front Cell Dev Biol"},{"issue":"21","key":"2285_CR43","first-page":"13392","volume":"16","author":"Y Ouyang","year":"2024","unstructured":"Ouyang Y, Wu Z, Aili D, Yang C, Zhang H, Wu T. Pan-cancer analysis identifies the oncogenic role of CCNE1 in human cancers. Aging (Albany NY). 2024;16(21):13392\u2013408.","journal-title":"Aging (Albany NY)"},{"issue":"1","key":"2285_CR44","doi-asserted-by":"publisher","first-page":"86","DOI":"10.1186\/s12957-021-02200-x","volume":"19","author":"Q Yuan","year":"2021","unstructured":"Yuan Q, Zheng L, Liao Y, Wu G. Overexpression of CCNE1 confers a poorer prognosis in triple-negative breast cancer identified by bioinformatic analysis. World J Surg Oncol. 2021;19(1):86.","journal-title":"World J Surg Oncol"},{"issue":"3","key":"2285_CR45","doi-asserted-by":"publisher","first-page":"e009239","DOI":"10.1136\/jitc-2024-009239","volume":"13","author":"S Yu","year":"2025","unstructured":"Yu S, Stappenbelt C, Chen M, Dekker M, Bhattacharya A, van der Sluis T, et al. Cyclin E1 overexpression triggers interferon signaling and is associated with antitumor immunity in breast cancer. J Immunotherapy Cancer. 2025;13(3):e009239.","journal-title":"J Immunotherapy Cancer"},{"issue":"7","key":"2285_CR46","doi-asserted-by":"publisher","first-page":"989","DOI":"10.1016\/j.ccell.2021.05.009","volume":"39","author":"L Pusztai","year":"2021","unstructured":"Pusztai L, Yau C, Wolf DM, Han HS, Du L, Wallace AM, et al. Durvalumab with olaparib and paclitaxel for high-risk HER2-negative stage II\/III breast cancer: Results from the adaptively randomized I-SPY2 trial. Cancer Cell. 2021;39(7):989-998.e985.","journal-title":"Cancer Cell"},{"issue":"15","key":"2285_CR47","doi-asserted-by":"publisher","first-page":"2484","DOI":"10.3390\/cancers17152484","volume":"17","author":"JS Pawar","year":"2025","unstructured":"Pawar JS, Salam MA, Dipto MSU, Al-Amin MY, Salam MT, Sengupta S, et al. Cancer-associated fibroblasts: immunosuppressive crosstalk with tumor-infiltrating immune cells and implications for therapeutic resistance. Cancers. 2025;17(15):2484.","journal-title":"Cancers"},{"key":"2285_CR48","doi-asserted-by":"publisher","first-page":"1568865","DOI":"10.3389\/fmolb.2025.1568865","volume":"12","author":"MR Brogna","year":"2025","unstructured":"Brogna MR, Varone V, DelSesto M, Ferrara G. The role of CAFs in therapeutic resistance in triple negative breast cancer: an emerging challenge. Front Mol Biosci. 2025;12:1568865.","journal-title":"Front Mol Biosci"},{"key":"2285_CR49","doi-asserted-by":"publisher","first-page":"1089068","DOI":"10.3389\/fcell.2023.1089068","volume":"11","author":"M Sarkar","year":"2023","unstructured":"Sarkar M, Nguyen T, Gundre E, Ogunlusi O, El-Sobky M, Giri B, et al. Cancer-associated fibroblasts: The chief architect in the tumor microenvironment. Front Cell Dev Biol. 2023;11:1089068.","journal-title":"Front Cell Dev Biol"},{"issue":"1","key":"2285_CR50","doi-asserted-by":"publisher","first-page":"404","DOI":"10.1038\/s41467-019-14134-w","volume":"11","author":"F Pelon","year":"2020","unstructured":"Pelon F, Bourachot B, Kieffer Y, Magagna I, Mermet-Meillon F, Bonnet I, et al. Cancer-associated fibroblast heterogeneity in axillary lymph nodes drives metastases in breast cancer through complementary mechanisms. Nat Commun. 2020;11(1):404.","journal-title":"Nat Commun"},{"issue":"2","key":"2285_CR51","doi-asserted-by":"publisher","first-page":"209","DOI":"10.1007\/s40265-016-0686-9","volume":"77","author":"LJ Scott","year":"2017","unstructured":"Scott LJ. Sitagliptin: a review in type 2 diabetes. Drugs. 2017;77(2):209\u201324.","journal-title":"Drugs"},{"key":"2285_CR52","doi-asserted-by":"publisher","first-page":"115193","DOI":"10.1016\/j.intimp.2025.115193","volume":"162","author":"J Tian","year":"2025","unstructured":"Tian J, Li Y, Wang Z, Zhong Y, Yao Y, Sun C. Antigen-presenting CAFs orchestrate immunosuppressive niches via CXCL13-mediated immune cell infiltration dysregulation and prognostic stratification in triple-negative breast cancer. Int Immunopharmacol. 2025;162:115193.","journal-title":"Int Immunopharmacol"},{"issue":"10","key":"2285_CR53","doi-asserted-by":"publisher","first-page":"e23696","DOI":"10.1096\/fj.202400578R","volume":"38","author":"M Chen","year":"2024","unstructured":"Chen M, Liu H, Hong B, Xiao Y, Qian Y. MIF as a potential diagnostic and prognostic biomarker for triple-negative breast cancer that correlates with the polarization of M2 macrophages. FASEB J. 2024;38(10):e23696.","journal-title":"FASEB J"},{"issue":"1","key":"2285_CR54","doi-asserted-by":"publisher","first-page":"44","DOI":"10.20892\/j.issn.2095-3941.2019.0210","volume":"17","author":"Z Wang","year":"2020","unstructured":"Wang Z, Jiang Q, Dong C. Metabolic reprogramming in triple-negative breast cancer. Cancer Biol Med. 2020;17(1):44\u201359.","journal-title":"Cancer Biol Med"},{"issue":"5","key":"2285_CR55","doi-asserted-by":"publisher","first-page":"477","DOI":"10.1038\/s41422-022-00614-0","volume":"32","author":"Y Xiao","year":"2022","unstructured":"Xiao Y, Ma D, Yang YS, Yang F, Ding JH, Gong Y, et al. Comprehensive metabolomics expands precision medicine for triple-negative breast cancer. Cell Res. 2022;32(5):477\u201390.","journal-title":"Cell Res"},{"issue":"7","key":"2285_CR56","first-page":"3041","volume":"13","author":"M Oshi","year":"2023","unstructured":"Oshi M, Roy AM, Yan L, Sasamoto M, Tokumaru Y, Wu R, et al. Accelerated glycolysis in tumor microenvironment is associated with worse survival in triple-negative but not consistently with ER+\/HER2- breast cancer. Am J Cancer Res. 2023;13(7):3041\u201354.","journal-title":"Am J Cancer Res"},{"key":"2285_CR57","doi-asserted-by":"publisher","first-page":"1424237","DOI":"10.3389\/fimmu.2024.1424237","volume":"15","author":"R Bao","year":"2024","unstructured":"Bao R, Qu H, Li B, Cheng K, Miao Y, Wang J. The role of metabolic reprogramming in immune escape of triple-negative breast cancer. Front Immunol. 2024;15:1424237.","journal-title":"Front Immunol"},{"key":"2285_CR58","doi-asserted-by":"publisher","first-page":"880959","DOI":"10.3389\/fimmu.2022.880959","volume":"13","author":"IJ Cohen","year":"2022","unstructured":"Cohen IJ, Pareja F, Socci ND, Shen R, Doane AS, Schwartz J, et al. Increased tumor glycolysis is associated with decreased immune infiltration across human solid tumors. Front Immunol. 2022;13:880959.","journal-title":"Front Immunol"},{"issue":"8","key":"2285_CR59","doi-asserted-by":"publisher","first-page":"e70520","DOI":"10.1096\/fj.202403019R","volume":"39","author":"P Liang","year":"2025","unstructured":"Liang P, Li Z, Chen Z, Chen Z, Jin T, He F, et al. Metabolic Reprogramming of Glycolysis, Lipids, and Amino Acids in Tumors: Impact on CD8+ T Cell Function and Targeted Therapeutic Strategies. FASEB J. 2025;39(8):e70520.","journal-title":"FASEB J"},{"issue":"5","key":"2285_CR60","doi-asserted-by":"publisher","first-page":"1284","DOI":"10.1158\/0008-5472.CAN-15-2478","volume":"76","author":"SO Lim","year":"2016","unstructured":"Lim SO, Li CW, Xia W, Lee HH, Chang SS, Shen J, et al. EGFR Signaling Enhances Aerobic Glycolysis in Triple-Negative Breast Cancer Cells to Promote Tumor Growth and Immune Escape. Cancer Res. 2016;76(5):1284\u201396.","journal-title":"Cancer Res"},{"key":"2285_CR61","doi-asserted-by":"publisher","first-page":"1216193","DOI":"10.3389\/fendo.2023.1216193","volume":"14","author":"J Repas","year":"2023","unstructured":"Repas J, Peternel L, Sourij H, Pavlin M. Low glucose availability potentiates the effects of metformin on model T cell activation and exhaustion markers in vitro. Front Endocrinol (Lausanne). 2023;14:1216193.","journal-title":"Front Endocrinol (Lausanne)"},{"issue":"1","key":"2285_CR62","doi-asserted-by":"publisher","first-page":"278","DOI":"10.1186\/s13046-024-03200-x","volume":"43","author":"G Li","year":"2024","unstructured":"Li G, Ma X, Sui S, Chen Y, Li H, Liu L, et al. NAT10\/ac4C\/JunB facilitates TNBC malignant progression and immunosuppression by driving glycolysis addiction. J Exp Clin Cancer Res. 2024;43(1):278.","journal-title":"J Exp Clin Cancer Res"},{"issue":"1","key":"2285_CR63","doi-asserted-by":"publisher","first-page":"58","DOI":"10.1182\/blood-2017-06-741033","volume":"131","author":"B Rowshanravan","year":"2018","unstructured":"Rowshanravan B, Halliday N, Sansom DM. CTLA-4: a moving target in immunotherapy. Blood. 2018;131(1):58\u201367.","journal-title":"Blood"},{"issue":"1","key":"2285_CR64","doi-asserted-by":"publisher","first-page":"16","DOI":"10.1007\/s00005-021-00618-5","volume":"69","author":"R Kern","year":"2021","unstructured":"Kern R, Panis C. CTLA-4 Expression and Its Clinical Significance in Breast Cancer. Arch Immunol Ther Exp (Warsz). 2021;69(1):16.","journal-title":"Arch Immunol Ther Exp (Warsz)"},{"issue":"1","key":"2285_CR65","doi-asserted-by":"publisher","first-page":"672","DOI":"10.1186\/s12967-024-05472-5","volume":"22","author":"Y Hu","year":"2024","unstructured":"Hu Y, Lou X, Zhang K, Pan L, Bai Y, Wang L, et al. Tumor necrosis factor receptor 2 promotes endothelial cell-mediated suppression of CD8+ T cells through tuning glycolysis in chemoresistance of breast cancer. J Transl Med. 2024;22(1):672.","journal-title":"J Transl Med"},{"issue":"2","key":"2285_CR66","first-page":"153","volume":"18","author":"A Nasir Kansestani","year":"2019","unstructured":"Nasir Kansestani A, Mansouri K, Hemmati S, Zare ME, Moatafaei A. High Glucose-reduced Apoptosis in Human Breast Cancer Cells Is Mediated by Activation of NF-\u03baB. Iran J Allergy Asthma Immunol. 2019;18(2):153\u201362.","journal-title":"Iran J Allergy Asthma Immunol"},{"key":"2285_CR67","doi-asserted-by":"publisher","first-page":"701006","DOI":"10.3389\/fimmu.2021.701006","volume":"12","author":"WT Zhou","year":"2021","unstructured":"Zhou WT, Jin WL. B7\u2013H3\/CD276: An Emerging Cancer Immunotherapy. Front Immunol. 2021;12:701006.","journal-title":"Front Immunol"},{"issue":"1","key":"2285_CR68","doi-asserted-by":"publisher","first-page":"153","DOI":"10.1186\/s13045-022-01364-7","volume":"15","author":"B Zhao","year":"2022","unstructured":"Zhao B, Li H, Xia Y, Wang Y, Wang Y, Shi Y, et al. Immune checkpoint of B7\u2013H3 in cancer: from immunology to clinical immunotherapy. J Hematol Oncol. 2022;15(1):153.","journal-title":"J Hematol Oncol"},{"issue":"4","key":"2285_CR69","doi-asserted-by":"publisher","first-page":"e010924","DOI":"10.1136\/jitc-2024-010924","volume":"13","author":"Y Jiang","year":"2025","unstructured":"Jiang Y, Qian Z, Wang C, Wu D, Liu L, Ning X, et al. Targeting B7\u2013H3 inhibition-induced activation of fatty acid synthesis boosts anti-B7-H3 immunotherapy in triple-negative breast cancer. J Immunotherapy Cancer. 2025;13(4):e010924.","journal-title":"J Immunotherapy Cancer"},{"issue":"4","key":"2285_CR70","doi-asserted-by":"publisher","first-page":"e140100","DOI":"10.1172\/JCI140100","volume":"131","author":"DN Edwards","year":"2021","unstructured":"Edwards DN, Ngwa VM, Raybuck AL, Wang S, Hwang Y, Kim LC, et al. Selective glutamine metabolism inhibition in tumor cells improves antitumor T lymphocyte activity in triple-negative breast cancer. J Clin Invest. 2021;131(4):e140100.","journal-title":"J Clin Invest"},{"key":"2285_CR71","doi-asserted-by":"publisher","first-page":"1251643","DOI":"10.3389\/fimmu.2023.1251643","volume":"14","author":"R Huang","year":"2023","unstructured":"Huang R, Wang H, Hong J, Wu J, Huang O, He J, et al. Targeting glutamine metabolic reprogramming of SLC7A5 enhances the efficacy of anti-PD-1 in triple-negative breast cancer. Front Immunol. 2023;14:1251643.","journal-title":"Front Immunol"},{"issue":"1","key":"2285_CR72","doi-asserted-by":"publisher","first-page":"27","DOI":"10.1007\/s00726-025-03456-3","volume":"57","author":"Y Zhao","year":"2025","unstructured":"Zhao Y, Pu C, Liu K, Liu Z. Targeting LAT1 with JPH203 to reduce TNBC proliferation and reshape suppressive immune microenvironment by blocking essential amino acid uptake. Amino Acids. 2025;57(1):27.","journal-title":"Amino Acids"},{"issue":"7824","key":"2285_CR73","doi-asserted-by":"publisher","first-page":"277","DOI":"10.1038\/s41586-020-2682-1","volume":"585","author":"Y Bian","year":"2020","unstructured":"Bian Y, Li W, Kremer DM, Sajjakulnukit P, Li S, Crespo J, et al. Cancer SLC43A2 alters T cell methionine metabolism and histone methylation. Nature. 2020;585(7824):277\u201382.","journal-title":"Nature"},{"issue":"1","key":"2285_CR74","doi-asserted-by":"publisher","first-page":"5","DOI":"10.1111\/imr.12858","volume":"295","author":"L Makowski","year":"2020","unstructured":"Makowski L, Chaib M, Rathmell JC. Immunometabolism: From basic mechanisms to translation. Immunol Rev. 2020;295(1):5\u201314.","journal-title":"Immunol Rev"},{"issue":"1","key":"2285_CR75","doi-asserted-by":"publisher","first-page":"180","DOI":"10.1186\/s13058-024-01932-4","volume":"26","author":"E Han","year":"2024","unstructured":"Han E, Choi HY, Kwon HJ, Chung YR, Shin HC, Kim EK, et al. Characterization of tumor-infiltrating lymphocytes and their spatial distribution in triple-negative breast cancer. Breast Cancer Res. 2024;26(1):180.","journal-title":"Breast Cancer Res"},{"issue":"2","key":"2285_CR76","doi-asserted-by":"publisher","first-page":"135","DOI":"10.1080\/14737140.2021.1840984","volume":"21","author":"J Sukumar","year":"2021","unstructured":"Sukumar J, Gast K, Quiroga D, Lustberg M, Williams N. Triple-negative breast cancer: promising prognostic biomarkers currently in development. Expert Rev Anticancer Ther. 2021;21(2):135\u201348.","journal-title":"Expert Rev Anticancer Ther"},{"issue":"2","key":"2285_CR77","doi-asserted-by":"publisher","first-page":"142","DOI":"10.1002\/path.4280","volume":"232","author":"BD Lehmann","year":"2014","unstructured":"Lehmann BD, Pietenpol JA. Identification and use of biomarkers in treatment strategies for triple-negative breast cancer subtypes. J Pathol. 2014;232(2):142\u201350.","journal-title":"J Pathol"},{"issue":"3","key":"2285_CR78","doi-asserted-by":"publisher","first-page":"375","DOI":"10.1046\/j.1365-2567.1996.d01-750.x","volume":"89","author":"JX Gao","year":"1996","unstructured":"Gao JX, Issekutz AC. Expression of VCAM-1 and VLA-4 dependent T-lymphocyte adhesion to dermal fibroblasts stimulated with proinflammatory cytokines. Immunology. 1996;89(3):375\u201383.","journal-title":"Immunology"},{"issue":"10","key":"2285_CR79","doi-asserted-by":"publisher","first-page":"4564","DOI":"10.7150\/thno.68972","volume":"12","author":"Y Wu","year":"2022","unstructured":"Wu Y, Yi Z, Li J, Wei Y, Feng R, Liu J, et al. FGFR blockade boosts T cell infiltration into triple-negative breast cancer by regulating cancer-associated fibroblasts. Theranostics. 2022;12(10):4564\u201380.","journal-title":"Theranostics"},{"issue":"8","key":"2285_CR80","doi-asserted-by":"publisher","first-page":"1785","DOI":"10.3390\/cells9081785","volume":"9","author":"YJ Cha","year":"2020","unstructured":"Cha YJ, Koo JS. Role of tumor-associated myeloid cells in breast cancer. Cells. 2020;9(8):1785.","journal-title":"Cells"},{"issue":"1","key":"2285_CR81","doi-asserted-by":"publisher","first-page":"78","DOI":"10.1038\/s41523-025-00799-8","volume":"11","author":"A Sharma","year":"2025","unstructured":"Sharma A, Sudan SK, Vikramdeo KS, Khan MA, Tahir M, Carter JE, et al. Subtype- and race-specific variations in the immune landscape of breast cancer: therapeutic implications. NPJ Breast Cancer. 2025;11(1):78.","journal-title":"NPJ Breast Cancer"},{"key":"2285_CR82","doi-asserted-by":"publisher","first-page":"1655176","DOI":"10.3389\/fimmu.2025.1655176","volume":"16","author":"S Mukherjee","year":"2025","unstructured":"Mukherjee S, Ghosh A, Chakraborty S, Basak U, Mukherjee S, Das T, et al. Tumor-infiltrating lymphocytes and tumor-associated macrophages in cancer immunoediting: a targetable therapeutic axis. Front Immunol. 2025;16:1655176.","journal-title":"Front Immunol"},{"issue":"10","key":"2285_CR83","doi-asserted-by":"publisher","first-page":"741","DOI":"10.3390\/cells14100741","volume":"14","author":"AF Saeed","year":"2025","unstructured":"Saeed AF. Tumor-associated macrophages: polarization, immunoregulation, and immunotherapy. Cells. 2025;14(10):741.","journal-title":"Cells"},{"issue":"1","key":"2285_CR84","doi-asserted-by":"publisher","first-page":"253","DOI":"10.7150\/ijms.120593","volume":"23","author":"Y Huang","year":"2026","unstructured":"Huang Y, Yu Y, Zhu Y, Lu Q, Zhang Z, Wang X, et al. Integration of single-cell and bulk transcriptome analyses unravels a macrophage-based gene signature for prognostication and treatment in triple-negative breast cancer. Int J Med Sci. 2026;23(1):253\u201370.","journal-title":"Int J Med Sci"},{"issue":"6","key":"2285_CR85","doi-asserted-by":"publisher","first-page":"510","DOI":"10.1158\/2326-6066.CIR-14-0072","volume":"2","author":"JL Lines","year":"2014","unstructured":"Lines JL, Sempere LF, Broughton T, Wang L, Noelle R. VISTA is a novel broad-spectrum negative checkpoint regulator for cancer immunotherapy. Cancer Immunol Res. 2014;2(6):510\u20137.","journal-title":"Cancer Immunol Res"},{"issue":"1","key":"2285_CR86","doi-asserted-by":"publisher","first-page":"40","DOI":"10.1038\/s41416-025-03013-5","volume":"133","author":"M Abudula","year":"2025","unstructured":"Abudula M, Astuti Y, Raymant M, Sharma V, Schmid MC, Mielgo A. Macrophages suppress CD8 + T cell cytotoxic function in triple negative breast cancer via VISTA. Br J Cancer. 2025;133(1):40\u201351.","journal-title":"Br J Cancer"},{"issue":"7779","key":"2285_CR87","doi-asserted-by":"publisher","first-page":"565","DOI":"10.1038\/s41586-019-1674-5","volume":"574","author":"RJ Johnston","year":"2019","unstructured":"Johnston RJ, Su LJ, Pinckney J, Critton D, Boyer E, Krishnakumar A, et al. VISTA is an acidic pH-selective ligand for PSGL-1. Nature. 2019;574(7779):565\u201370.","journal-title":"Nature"},{"key":"2285_CR88","doi-asserted-by":"publisher","first-page":"1291643","DOI":"10.3389\/fimmu.2023.1291643","volume":"14","author":"MR Moamin","year":"2023","unstructured":"Moamin MR, Allen R, Woods SL, Brown JE, Nunns H, Juncker-Jensen A, et al. Changes in the immune landscape of TNBC after neoadjuvant chemotherapy: correlation with relapse. Front Immunol. 2023;14:1291643.","journal-title":"Front Immunol"},{"issue":"1","key":"2285_CR89","doi-asserted-by":"publisher","first-page":"128","DOI":"10.1186\/s43556-025-00372-6","volume":"6","author":"Y Yang","year":"2025","unstructured":"Yang Y, Liu Z, Kaysar P, Han Y, Ni B, Li L, et al. Delta-like ligand 4 mediated myeloid-derived suppressor cell metabolic reprogramming promotes neoadjuvant therapy resistance in titin-inactivated triple-negative breast cancer. Mol Biomed. 2025;6(1):128.","journal-title":"Mol Biomed"},{"key":"2285_CR90","first-page":"523","volume":"17","author":"A Agelidis","year":"2025","unstructured":"Agelidis A, Ter-Zakarian A, Jaloudi M. Triple-Negative Breast Cancer on the Rise: Breakthroughs and Beyond. Breast Cancer (Dove Med Press). 2025;17:523\u20139.","journal-title":"Breast Cancer (Dove Med Press)"},{"key":"2285_CR91","doi-asserted-by":"crossref","unstructured":"Miller KD, Thomas A, Althouse S, Zang Y, Conder E, Burgos R, Schneider BP, Ballinger T, Douglas E, Ansley K et al: A Phase I Study of ASTX727 plus Talazoparib in Patients with Triple Negative or Hormone Resistant\/HER2-negative Metastatic Breast Cancer. medRxiv 2025:2025.2009.2009.25335318.","DOI":"10.1101\/2025.09.09.25335318"},{"issue":"11","key":"2285_CR92","doi-asserted-by":"publisher","first-page":"3037","DOI":"10.1007\/s11010-023-04907-9","volume":"479","author":"LL Jin","year":"2024","unstructured":"Jin LL, Lu HJ, Shao JK, Wang Y, Lu SP, Huang BF, et al. Relevance and mechanism of STAT3\/miR-221-3p\/Fascin-1 axis in EGFR TKI resistance of triple-negative breast cancer. Mol Cell Biochem. 2024;479(11):3037\u201347.","journal-title":"Mol Cell Biochem"},{"issue":"23","key":"2285_CR93","doi-asserted-by":"publisher","first-page":"e202500740","DOI":"10.1002\/cmdc.202500740","volume":"20","author":"BD Ellenbroek","year":"2025","unstructured":"Ellenbroek BD, Tirtosentono ASS, Pomplun SJ. AlphaFold-Guided Discovery of an Overlapping MYC\/Miz-1 Interface Enables Peptidomimetic Disruption of MYC\/MAX. ChemMedChem. 2025;20(23):e202500740.","journal-title":"ChemMedChem"},{"issue":"7","key":"2285_CR94","doi-asserted-by":"publisher","first-page":"530","DOI":"10.3390\/cells14070530","volume":"14","author":"S Mielcarska","year":"2025","unstructured":"Mielcarska S, Kot A, Kula A, Dawidowicz M, Sobk\u00f3w P, K\u0142aczka D, et al. B7H3 in gastrointestinal tumors: role in immune modulation and cancer progression: a review of the literature. Cells. 2025;14(7):530.","journal-title":"Cells"},{"issue":"16","key":"2285_CR95","doi-asserted-by":"publisher","first-page":"3581","DOI":"10.1158\/1078-0432.CCR-25-0634","volume":"31","author":"C Li","year":"2025","unstructured":"Li C, Yao J, Yang J, Zhang Y, Qiu Y, Zhu Z, et al. Preclinical evaluation of DB-1419, a novel bifunctional and bispecific anti-B7-H3 x PD-L1 antibody-drug conjugate. Clin Cancer Res. 2025;31(16):3581\u201393.","journal-title":"Clin Cancer Res"}],"container-title":["Breast Cancer Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s13058-026-02285-w","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13058-026-02285-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13058-026-02285-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,6,16]],"date-time":"2026-06-16T22:45:37Z","timestamp":1781649937000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1186\/s13058-026-02285-w"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,4,26]]},"references-count":95,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["2285"],"URL":"https:\/\/doi.org\/10.1186\/s13058-026-02285-w","relation":{},"ISSN":["1465-542X"],"issn-type":[{"value":"1465-542X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,4,26]]},"assertion":[{"value":"16 December 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"9 April 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"26 April 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"All authors consent to publication.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"109"}}